DeepIntent Survey Reveals That Pharmaceutical Advertising Motivates Patients to Research Treatment and Medication Options

NEW YORK, Oct. 27, 2021 — DeepIntent, the leading independent healthcare marketing technology company built purposefully to influence patient health and business outcomes, today released survey findings that reveal new insight into patient sentiment related to pharmaceutical advertising and the headwinds marketers face in trying to deliver relevant content.

Building on research conducted earlier this year, DeepIntent surveyed 1,244 U.S. patients in August 2021 and found that pharmaceutical ads can empower patients to take a more active role in researching treatments. In addition, advertising influences patients’ decision to follow through in taking drugs prescribed by their doctors. After seeing a pharmaceutical ad, patients’ most common action is conducting research, which they state as the most common factor influencing their medication adherence behavior. This finding ranks higher than their previous experience taking the same drug.

However, the research also found that marketers face significant challenges in reaching the right groups of patients with relevant information. Despite the pharmaceutical industry’s success in researching, producing, and distributing multiple COVID-19 vaccines in less than a year, public approval of pharmaceutical companies has remained flat, and nearly half of respondents don’t trust information from pharmaceutical companies. Amid the challenge to capture patients’ attention while overcoming their distrust of ads and the pharmaceutical industry, the research shows several paths to better connect with patients.

Key survey findings include:

  • More than half (51%) of respondents said an ad was more memorable when relevant to their medical conditions.
  • Non-white respondents were more likely to agree that having seen a pharmaceutical ad made them feel more informed to discuss it as an option with their doctor.
  • One in three patients (37%) report that they have noticed more ads served to them over the past 12 months, with Americans over 55 the most likely to report seeing more pharmaceutical ads (50%).
  • Patients over 55 were the most likely to report online research as a factor in prescription follow-through (40%) and were the group most likely to report that they always took prescription medications prescribed by their doctor (41%).

“The insights from our second patient research report highlight a massive opportunity in the healthcare marketing industry to use advertising as a tool for public health. Over the past several years, the healthcare data ecosystem has been undergoing a transformative change and with real-world health data, real-time programmatic advertising, and modern technologies like artificial intelligence, marketers can engage both patients and providers in a more personalized, effective way,” said DeepIntent CEO Chris Paquette. “We have evidence that more relevant advertising drives real results for our clients and, as we’ve seen with two surveys now, relevant advertising also has the power to improve the lives of patients by educating them about conditions and treatment options. With that commitment to personalization in a privacy-safe way, DeepIntent will continue to innovate, pushing our industry forward and driving positive outcomes for patients and our clients.”

Download the complete research report here.

About DeepIntent
Conceived by former Memorial Sloan Kettering data scientists, DeepIntent connects healthcare companies with patients and providers across every device through unique data, media partnerships, and integrations. From campaign planning to audience targeting to optimization and measurement, DeepIntent is proven to drive higher audience quality and script performance while improving patients’ quality of life. Its Healthcare Marketing Platform empowers marketers at eight of the top ten pharmaceutical companies and leading healthcare advertising agencies to transact highly effective digital healthcare campaigns, positively influencing health and business outcomes. For more information, visit or find us on Twitter, Facebook, or LinkedIn.

Press Contact
Finn Partners for DeepIntent
Mena Buscetto
[email protected]

More News

Press Release
DeepIntent Joins the Network Advertising Initiative (NAI)
Supports New Guidelines for Health Advertising NEW YORK, November 14, 2023 — Healthcare advertising technology leader DeepIntent announced its membership in the Network Advertising...
Read More
Press Release
The Ad Council Appoints 18 New Members to its Board of Directors
NEW YORK, October 31, 2023 — The Ad Council has elected 18 new members to its board of directors, which is chaired by Verizon...
Read More
Press Release
DeepIntent Wins AdExchanger Award for Best Demand-Side Technology
Purposefully built for the pharmaceutical industry, the DeepIntent Healthcare Advertising Platform is proven to drive higher audience quality and script performance NEW YORK, October...
Read More